[PharmakonNewsWire] The worldwide release of Atramabor, the flagship drug of nascent startup Trinity Pharmacopoeia, has come under fire from a series of lawsuits. Trinity Pharmacopoeia, a privately held integrated biopharmaceutical company with offices in New York, Rome, and Hyderabad, has been recently named in five separate infringement lawsuits.

Four have been filed by Entheomimesis, Inc., based out of Menlo Park, California, and they focus on the development patents held by Trinity, alleging that the distillation and extraction methodologies outlined in the patents are so broadly written that they prohibit other companies from utilizing any manner of distillation process.

Entheomimesis's final lawsuit seeks an injunction against the sale of Atramabor, which is scheduled to become available to pharmacies and psychiatrists by the end of the financial quarter. "The chemical composition of Atramabor's active ingredient is a known psychotropic, one that is naturally occurring," says Dr. Bertrand Childress, Chief Medical Officer of Entheomimesis. "The fact that they have been allowed to patent this compound is the equivalent of allowing a baker to patent the donut. It's a preposterous and ludicrous attempt by Trinity Pharmacopoeia to monopolize the emerging field of nootropic pharmaentheogenics."

The fifth lawsuit has been filed the Umbrial Consortium, a U.S. based LLC representing the Ehrillimbal family. Similarly, the Umbrial lawsuit contests the patent issued for Atramabor, echoing Entheomimesis' argument that the chemical foundation of the drug is a naturally occurring compound. Additionally, this lawsuit accuses the Trinity Foundation of plagiarizing methods and data from a series of articles published in The Journal of Exploratory and Experimental Pharmacology in 1958.

The articles in question were written by Dr. Julio Ehrillimbal and were a series of monographs collecting his research data and observations from a year-long expedition in Peru and Brazil. The Journal of Exploratory and Experimental Pharmacology ceased publication in 1965, following an office fire that claimed the life of Dr. Ehrillimbal who was Editor-in-Chief of the publication at that time. The historical archive of the journal was also destroyed in that fire.

Trinity Pharmacopoeia did not return calls requesting comments on the pending litigation. Atramabor is a neurological agent that is intended to repair the fragmentary psychosis associated with schizophrenia. Market analysis projects a cap of $260 Million USD from first year sales of the drug. Trinity Pharamacopoeia was recently under public scrutiny over allegations that their clinical trials for Atrambor were conducted illegally and without patient consent. That lawsuit was settled late last year after FDA investigators and an independent mediator found no discrepancies or irregularities in Trinity's clinical trail proceedings or manufacturing process.